We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
МОНОКЛОНАЛНИ АНТИТЕЛА В ПЕДИАТРИЯТА.
- Authors
Маринов, Л.; Мангъров, И.
- Abstract
Monoclonal antibodies (mAbs) are biologic drugs that are widely used in all age groups to treat diseases such as rheumatic, autoinflammatory and oncological diseases. They are increasingly used in pediatrics and those with approved pediatric indications is steadily increasing. mAbs are not the first-line drug of choice in any pediatric indication, with the exception of palivizumab. In addition, the pharmacokinetics and pharmacodynamics of mAbs are influenced by the features of the pediatric organism, which is also the reason for specific dosing differences. Dosing based on body size is used for more than half of the mAbs, as this approach results in a reduction in drug inter-subject variability. No high-quality well-controlled clinical studies are available for most mAbs in the pediatric population. Adverse drug reactions for mAbs differ from those induced by other drugs, like ‚small molecules‘. mAbs act as autologous proteins rather than as chemical compounds. All mAbs, as therapeutic proteins, have the potential to induce an immune response with single or repeated administration. With an increasing number of mAbs approved with pediatric indications, there is a growing knowledge base on the pharmacokinetics and clinical pharmacology of this class of compounds in pediatric patient populations of various ages.
- Subjects
DRUG side effects; SMALL molecules; PALIVIZUMAB; CHILD patients; MONOCLONAL antibodies
- Publication
Medical Review / Meditsinski Pregled, 2022, Vol 58, Issue 5, p19
- ISSN
1312-2193
- Publication type
Article